Comparative study reveals cysteine pegylation improves enzyme activity and stability, suggesting a promising biobetter approach.
L-asparaginase (ASNase) is one of the most clinically relevant biopharmaceuticals but proteolysis impairs the enzyme half-life. ASNase P40S/S206C was developed to overcome proteolysis and in addition pegylation can be used to improve half-life and thermostability. Here Cys206 and N-terminal residues were explored as pegylation sites for a potential new biobetter. Optimal mono-pegylation of Cys (Cys-PEG-ASNase) provided similar yields compared to N-terminal mono-pegylation (NT-PEG-ASNase) but at lower PEG concentration. Specific activity was higher for Cys-PEG-ASNase than NT-PEG-ASNase. The role of pegylation site in activity was confirmed by activation energy ( Ea ) and enthalpy variation (Δ H 70ºC ) of the ASNase-catalysed reaction. Pegylation in both sites increased enzyme thermostability and consequently shelf-life stability. The variation of Gibbs free-energy of enzyme thermo-inactivation (Δ G d ) showed higher stabilization by Cys conjugation, while enthalpy (Δ H d ) and entropy (Δ S d ) evidenced an increase in aggregation upon thermo-inactivation, higher for Cys-PEG-ASNase.
No takes yet. Share an insight, caveat, or question.
Ferraro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: